NEUROD1 antibody - N-terminal region (ARP32036_T100)
- Known as:
- NEUROD1 (anti-) - N-terminal region (ARP32036_T100)
- Catalog number:
- arp32036_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- NEUROD1 antibody - N-terminal region (ARP32036_T100)
Related genes to: NEUROD1 antibody - N-terminal region (ARP32036_T100)
- Gene:
- NEUROD1 NIH gene
- Name:
- neuronal differentiation 1
- Previous symbol:
- NEUROD
- Synonyms:
- BETA2, BHF-1, NeuroD, bHLHa3, MODY6
- Chromosome:
- 2q31.3
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2019-04-23
Related products to: NEUROD1 antibody - N-terminal region (ARP32036_T100)
Related articles to: NEUROD1 antibody - N-terminal region (ARP32036_T100)
- Inducible T cell costimulator ligand (ICOSLG) regulates T cell functional states, yet its role in small cell lung cancer (SCLC) remains poorly characterized. By integrating multiple cohorts, we found that high tumor-intrinsic ICOSLG was associated with poor overall survival (OS) in the TU-SCLC cohort ( = 0.010) and the Wang et al. cohort ( < 0.001), and was associated with inferior efficacy to chemo-immunotherapy (hazard ratio [HR] = 2.66, = 0.008). Consistently, the ICOSLG high subgroup exhibited significantly reduced functional CD8 T cell infiltration, elevated exhausted CD8 T cells, decreased effector molecules such as GZMK and IFNG, and enrichment of malignant pathways, including hypoxia, epithelial-mesenchymal transition, and others. Meanwhile, the correlation between ICOSLG and NEUROD1 expression was observed. On the contrary the subgroup high in ICOS, the main ICOSLG receptor, harbored NOTCH pathway mutations, showed an inflamed tumor microenvironment, better prognosis, and prolonged OS with chemo-immunotherapy (HR = 0.52, = 0.003). Dual ICOSLG and ICOS stratification revealed that the ICOSLG low and ICOS high subgroup derived the greatest benefit from chemo-immunotherapy (median OS: 17.2 vs. 9.8 months; < 0.001). Collectively, this dual-stratification strategy refined patient selection for chemo-immunotherapy, unveiled actionable targets, and ultimately advanced precision immunotherapy in SCLC. - Source: PubMed
Publication date: 2026/05/28
Guo QijiChen YanSun JijunZhang HongyiJi ShuyuYu HuanshaZhang LeleHu HaiyangZhang PengZhang Jing - Temozolomide (TMZ) is used to treat glioblastoma cancer and it is essential to identify key genes and investigate the molecular mechanisms of glioblastoma cancer cells resistant to temozolomide. - Source: PubMed
Publication date: 2026/06/05
Alamholo MostafaTarinejad Alireza - The olfactory epithelium (OE) maintains lifelong neurogenesis and shows strong regenerative capacity through the coordinated functions of horizontal basal cells (HBCs) and globose basal cells (GBCs). These progenitors are regulated by key transcriptional factors such as Sox2, p63, Pax6, Ascl1, Neurog1 and NeuroD1, as well as signaling pathways including Wnt/β-catenin, Notch, YAP and inflammation-related regulators, which together control lineage specification and injury-induced plasticity. A set of genes such as Lgr5, Tmem59, Notch1, and Chil4 play critical roles in OE homeostasis and regeneration, depending on a broader and highly dynamic network. Recent progress in single-cell transcriptomics, spatial transcriptomics and organoid models has revealed previously unrecognized cell states, differentiation routes and intercellular communications. This review summarizes the molecular and cellular mechanisms that support OE regeneration and highlights emerging technologies that advance understanding the process of olfactory epithelium regeneration and guiding future approaches for restoring olfactory function. - Source: PubMed
Publication date: 2026/06/02
Qi JiamingYu Yiqun - Small cell neuroendocrine carcinomas occur in both pulmonary (SCLC) and extrapulmonary sites (EP-SCNC). Although morphologically similar, they may differ biologically, but these differences are not well characterized. The aim of this study was to compare cohorts of SCLC (n = 215) and EP-SCNC(n = 184) with respect to molecular alterations, RNA and protein expression in tumor tissue. The median survival for SCLC was 6.3 months and 8.9 months for EP-SCNC patients (p < 0.0001). Genetic alterations of TP53, RB1, and KMT2D were the most common in both groups. The TP53 mutation was associated with worse survival in EP-SCNC (HR = 1.62; p = 0.043), while KMT2D was associated with worse survival in SCLC (HR = 1.62; p = 0.003). The tumor mutation burden (TMB) was higher in SCLC (p < 0.001). In RNA-Seq analyses, SCLC and EP-SCNC formed distinct RNA clusters. A total of 553 genes were differentially expressed. snoRNAs and tRNAs were predominantly upregulated in SCLC. GOAT analysis revealed upregulation in cell signaling and cellular plasticity in EP-SCNC, whereas SCLC showed enhanced transcriptional activity, including RNA processing and nuclear functions. Immunohistochemistry revealed higher expression of ASCL1 and NEUROD1 in SCLC than in EP-SCNC. YAP1 and POU2F3 expressions were higher in EP-SCNC. In multivariate analyses, EP-SCNC was associated with better survival, greater molecular heterogeneity, and distinct genetic, transcriptional, and immunohistochemical profiles. These findings demonstrate that, despite their morphological similarity, the two tumor groups are biologically distinct. - Source: PubMed
Publication date: 2026/05/25
Pavlíčková KláraHojný JanHájková NikolaWaldauf PetrDundr PavelDrosslerová MarieŠvajdler MariánFabian PavelStružinská IvanaKrkavcová EvaDvořák JiříMichálková RomanaZambo Iva StaniczkováFlídrová MiroslavaLaco JanHornychová HelenaDelongová PatricieŠkarda JozefHrudka JanMatěj Radoslav - Olfactory Neuroblastoma (ONB) is a rare and aggressive malignant tumor with a complex, heterogeneous pathogenesis. Although various omics studies have been conducted for ONB recently, there is still no omics evidence summary for ONB. Therefore, this study systematically reviews and synthesizes evidence across multiple omics layers for identifying biomarkers and therapeutic targets of ONB, aiming to advance the translation of molecular insights into clinical applications, including subtype classification, targeted therapy, and drug development. - Source: PubMed
Publication date: 2026/05/28
Deng NingChen ZehaoUng Carolina Oi LamLai YunfengSong MenghuanHu Hao